Orthocell received a new patent in Singapore titled "Method for Producing a Collagen Membrane and Uses Thereof," relative to the CelGro® soft tissue reconstruction platform.
Six-month results from Phase I/II study indicate that RepliCel’s RCT-01 fibroblasts demonstrated product safety and clinical potential for tendon regeneration and healing.
Earlier this year, an ORTHOWORLD Member asked us: What portion of new products introduced in joint reconstruction and spine are additively manufactured? Here's what our analysis shows.